Reuter H D, Thiele S
Arzneimittelforschung. 1986 Jul;36(7):1144-7.
Concentrations of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinoline carboxylic acid (ciprofloxacin; designated tradename: Ciprobay) similar to maximal levels obtained in the serum of patients with intact renal function after application of therapeutic doses and 4- to 5-fold such concentrations do not influence epinephrine- or collagen-induced aggregation. 100 micrograms/ml ciprofloxacin, corresponding to the 20 fold maximal serum level of patients with intact renal function, does not influence aggregation induced by 2 micrograms/ml collagen as regards degree and kinetics of aggregation, while aggregation induced by 0.2 micrograms/ml collagen is significantly reduce. Aggregation induced by 1, 2 and 4 mumol/l epinephrine is also reduced significantly by 100 micrograms/ml ciprofloxacin. Changes brought about by high doses of ciprofloxacin still occur within the normal range. It is therefore concluded from this study that the hemostatic function of the platelets is not influenced in a clinically relevant manner by ciprofloxacin. Regarding the effect on platelet aggregation ciprofloxacin corresponds to the structurally related pipemidic acid.
1-环丙基-6-氟-1,4-二氢-4-氧代-7-(1-哌嗪基)-3-喹啉羧酸（环丙沙星；商品名：拜复乐）的浓度与肾功能正常患者应用治疗剂量后血清中获得的最高水平相似，且4至5倍于此的浓度不会影响肾上腺素或胶原蛋白诱导的聚集。100微克/毫升的环丙沙星相当于肾功能正常患者血清最高水平的20倍，就聚集程度和动力学而言，其不会影响2微克/毫升胶原蛋白诱导的聚集，而0.2微克/毫升胶原蛋白诱导的聚集则会显著减少。100微克/毫升的环丙沙星也会显著降低1、2和4微摩尔/升肾上腺素诱导的聚集。高剂量环丙沙星引起的变化仍在正常范围内。因此，从这项研究可以得出结论，环丙沙星不会以临床相关方式影响血小板的止血功能。关于对血小板聚集的影响，环丙沙星与结构相关的吡哌酸相当。
